Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study aims to assess sodium glucose linked transoprter inhibitors(SGT2i) role in
regression of ongoing kidney and cardiac diseases among lupus nephritis patient either
diabetic or non-diabetic under different immunosuppressive therapy.
The main objective of this study is to:
To compare use of sodium glucose linked transoprter inhibitors (SGLT2i) versus standard care
in regression of chronic kidney disease in patient with lupus nephritis (LN).
To study the safety and efficacy of this drug group with use of immunosuppression and
possible interaction.
Patients with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73m2 will be
randomized into two groups Study group will receive SGLT2i inhibitor as add on drug or
replace another drug according to patient clinical situation, Dapagliflozin 10 mg and 25 mg
will be used once daily with or without food.
Control group will be maintained on placebo.We will follow up all patients for 12 months and
compare their results.